drugset / Trial / NCT00541242

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

NCT00541242

Phase 4 Completed 586 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension

Timeline

Start
2007-12
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bimatoprost Other / unclassified 0.03 % Topical
Comparator Latanoprost Small molecule 0.005 % Topical